Abstract: Systems and methods are provided for determining whether and/or when a patient is taking his or her medication and, when appropriate, providing reminders and/or alerts to the patient to improve adherence to a medication regimen. In some embodiments, a medication container is provided that includes a capacitance sensor for sensing the contents of the medication container (e.g., pill count or quantity of liquid medication). The capacitance sensor may include interleaved or interdigitated electrodes oriented vertically, horizontally, or angularly (e.g., diagonally) relative to an axis of the medication container. Reminders and/or alerts to the patient may be triggered based at least in part on the contents of the medication container, when a cap of the container was last opened and/or closed, the location of the medication container, and/or the container's surroundings.

Abstract: A milk paci comprises a thermos which is divided into two different sections, a first or top section for cooling and a second or lower section for heating. The first and second sections further define receptacles for temporarily placing or housing one or more baby pacifiers for achieving a desired section temperature. The thermos is mounted to a base portion which houses the circuitry, rechargeable batteries and switches used for managing thermos temperature control. In use, the first or top section of the thermos is used for cooling milk wherein the second or lower section is used for heating the milk. Cooling and heating is done with the help of the batteries and switches used simultaneously wherein the heating temperature is accurately monitored and controlled by sensors and circuitry housed within the thermos base portion.

Abstract: A flexible sealing lid and connector device for a drink container includes a container attachment band for wrapping around and attaching to the drink container. A resiliently flexible lid component is interconnected by a flexible connector element to the container attachment band. The lid component includes a neck portion for resiliently expanding to receive and sealably grip a periphery of the drink container such that the lid component covers a liquid dispensing opening of the drink container.

Abstract: A percutaneous endoscopic gastrostomy feeding tube is supported with a lanyard connected to a first connector; wherein the first connector operably supports a PEG tube. The first connector may be attached to one or more additional connectors interposed between the lanyard and the primary connector. One or more of the connectors may be a clamp of the type that is biased to the closed, i.e. grasping configuration, and when manually pinched the clamp is opened. Connectors may include one or more clamps of the type the may be locked in the closed, i.e. clamping, position. Connector may include one or more hooks, loops, or straps.

Abstract: A root canal filling material incorporates heat conductive particles of sub-micron size dispersed in a heat flowable matrix of endodontic filling material. The particle size is 1 micron or less (e.g., 0.5 to 1 micron, or nanoparticles of 100 nm or less). The addition of high heat conductive particles in the heat flowable matrix material improves the overall heat conductivity of the root canal filling material. During root canal treatment procedure, the filling material softens more thoroughly to fill the root canal apex and to form a seal of higher integrity at the root canal apex area, at a significantly lower operating temperature. The inventive filling material may be provided in bulk (e.g., pellet form) for use with an injection tool that heats and injects softened filling material into root canal cavities, or pre-shaped in the form of dental root canal filling cones (or points).

Abstract: A method of forming a stabilized calcium phosphate moiety for use in dental or biomedical applications includes providing a solution or dispersion including a calcium salt and reacting an organic phosphate having a polymerizable methacrylate or vinyl group with the solution or dispersion in order to form the calcium phosphate moiety having at least one pendant polymerizable group and at least one organic functional group, which may be the same group. A polymerizable composite system having a stabilized calcium phosphate formed according to the method is also provided.

Abstract: Dental composite comprising (i) a polymerizable composition obtainable by reacting a mixture comprising: (a) x equivalents of one or more compounds of the following formula (I): wherein L? is an (l+1)-valent hydrocarbon group which may contain in its backbone 1 to 3 heteroatoms selected from oxygen atoms and sulfur atoms and which may be substituted by one or more hydroxyl groups or groups —COOL? wherein L? is a polymerizable moiety; l is an integer of from 1 to 3; (b) y equivalents of one or more compounds of the following formula (IIa), (IIb) and/or (IIc): wherein n is an integer of from 1 to 3, Y may be present or absent, and when present represents a carbonyl group; Y? independently may be present or absent, represents a carbonyl group; Rm which may be the same or different represent 1 to 3 substituents selected from halogen atoms, alkyl groups, and alkoxy groups, or wherein two Rm form together with the carbon atoms of the ring to which they are bonded an annelated aromatic ri

Abstract: Examples and methods of providing hair conditioning compositions with microcapsules are described herein, in particular, with reference to the ratio of the encapsulated perfume oil to solute in the composition.

Abstract: Examples and methods of providing hair conditioning compositions with microcapsules are described herein, in particular, with reference to the ratio of the encapsulated perfume oil to solute in the composition.

Abstract: A cosmetic treatment method, and a device therefor, are provided that allow for cosmetic treatment of cosmetic disorders, caused by chronological age, environmental factors, changes in physiological functions of skin, such as psoriasis, dermatitis, acne, cellulites, and viral and/or bacteriological attacks. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the area to be cosmetically treated, such that a cosmetic dose of nitric oxide is eluted from said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said cosmetic dosage of nitric oxide (NO). Furthermore, a manufacturing method for said device is provided.

Abstract: The present invention relates to a composition for topical application consisting of an aqueous phase and an oily phase, which are separate and transparent, comprising at least one surfactant that is liquid at room temperature and at atmospheric pressure, with an HLB <8 and chosen from fatty acid esters of sugar and alkyl polyglucosides, at least one branched alkane comprising from 8 to 18 carbon atoms, and from 0 to 4% by weight of silicone oils relative to the total weight of the composition. The composition according to the invention makes it possible to obtain, after shaking, an emulsion that rapidly separates again into two transparent phases, having a perfectly sharp interface and with no appearance of droplets that remain attached to the walls of the transparent container. The composition in accordance with the invention has the same makeup-removing efficacy and better sensory properties, and in particular it leaves less greasy residue on the skin.

Abstract: Provided are methods of treating skin with at least two alternating treatment modalities to improve the health and/or diminish signs of aging. Some methods according to the present invention may comprise topically applying at least two separate compositions, in a sequential, rotating, or alternating fashion to overcome adaptation, tolerance, or sensitization phenomena.

Abstract: Provided are methods of treating skin with at least two alternating treatment modalities to improve the health and/or diminish signs of aging. Some methods according to the present invention may comprise topically applying at least two separate compositions, in a sequential, rotating, or alternating fashion to overcome adaptation, tolerance, or sensitization phenomena.

Abstract: A formulation and use thereof in reducing hair loss on the scalp of a human subject, where the formulation contains at least one penetration enhancer effective in reducing hair loss when applied topically to a scalp.

Abstract: The present disclosure relates, according to some embodiments, to photostable UV absorbing compositions comprising para-alkoxyl phenyl substituted propenoic acid (APP) derivatives. Furthermore, the present disclosure relates to methods of prolonging the UV absorption capabilities of a composition using photostable UV absorbing compositions comprising APP derivatives.

Abstract: The present invention describes cosmetic nanotechnology, comprising polymeric nanoparticles containing oil and UV filter, photoprotective compositions comprising polymeric nanoparticles described herein, methods of prevention of diseases of the skin, and processes for the preparation of the polymeric nanoparticles described herein.

Abstract: An agent for hair dyeing or bleaching includes (A) (a1) from 10 to 30% by weight oil which is in a liquid form at normal temperature and (a2) an oil which is in a solid form at normal temperature, which includes a higher alcohol which is in a solid form at normal temperature, and the weight ratio (A)/(a2) of the total weight (A) of (a1) and (a2) to (a2) is from 3 to 8; (B) (b1) a cationic surfactant and (b2) a nonionic surfactant, wherein the cationic surfactant includes an alkyltrimethylammonium chloride which has from 16 to 22 carbon atoms in the alkyl group thereof, and the total weight (B) of (b1) and (b2) is from 0.5 to 1.8% by weight, and (C) from 0.1 to 12% by weight of an oxidizing agent, wherein, the weight ratio (A)/(B) of (A) to (B) is from 5 to 30.

Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

Abstract: A cosmetic product with demonstrated DNA-repair properties, which has a mixture of liposomes that incorporate as active ingredients different DNA-repair enzymes and a combination of amino acids and zinc salt in addition to other components for cosmetic use.

Abstract: Disclosed is the use of glycosaminoglycan esters, whose alcohol groups are partly esterified with lipoic acid or with lipoic acid and formic acid, in hair care treatments.

Abstract: A mascara composition including an olefin/acrylate grafted polymer and a styrene/acrylates copolymer. Preferably, the ratio of the weight amount of the olefin/acrylate grafted polymer to the weight amount of the styrene/acrylates copolymer is from about 1:3 to about 4:1.

Abstract: A mascara composition including at least one olefin/acrylate grafted polymer and at least one acrylates copolymer. The ratio of the weight amount of the olefin/acrylate grafted polymer to the weight amount of the acrylates copolymer in the mascara composition is preferably from about 0.85 to about 4.5.

Abstract: The invention is a cosmetic or dermatological preparation and the use thereof, said preparation comprising a combination of a) glycoprotein 1, b) glycoprotein 2, ginseng extract and d) equisetum extract, to protect the skin against extrinsic skin aging.

Abstract: Described herein are systems, methods and embodiments associated with the use of biomass for generating a preparation that can be used in manufacture of a personal care product. The described embodiments include collection of evidence of toxic cyanobacteria presence within biomass. Upon identification of biomass containing toxic cyanobacteria, embodiments describe processing of the biomass which will ultimately lead to the preparation. Thereafter, regardless of the initial presence of toxins, once the biomass is processed, the preparation can be safely used within a personal care product.

Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.

Abstract: The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.

Abstract: Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either.

Abstract: A dosage form article suitable for oral administration may include more than one compartment, each formed by a plurality of distinct segments of the dosage form article. The dosage form article may also include a signaling means and a drug, wherein the signaling means and the drug are each stored in different compartments physically separated from one another. Both the drug and the signaling means may be wholly incorporated within the dosage form article, the respective compartments being arranged to fully enclose the drug and signaling means only when at least two of the plurality of distinct segments are connected.

Abstract: The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ?1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 35 to 60° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.

Abstract: The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.

Abstract: A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer.

Abstract: This invention teaches a novel treatment of patients infected with influenza virus in early stages of the disease, with liposomes called ?-gal/SA liposomes, in order to decrease the infection period and decrease further complications by this disease. The treatment is based on inhalation of biodegradable liposomes that present two types of carbohydrate epitopes: ?-Gal epitopes with the structure Gal?1-3Gal?1-4(3)GlcNAc-R) and sialic acid (SA) epitopes. The treatment is based on the ability of influenza virus to bind to SA epitopes and on the binding of the natural anti-Gal antibody (the most abundant natural antibody in humans) to ?-gal epitopes. Following inhalation of aerosolized ?-gal/SA liposomes they land in the mucus lining the respiratory tract. The ?-gal/SA liposomes bind influenza virus via SA epitopes interaction with hemagglutinin of the virus, thus they slow or prevent the progress of the influenza virus infection process.

Abstract: Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer.

Abstract: A particulate cellulose derivative is obtained in a process of grinding and drying a moist cellulose derivative which comprises the steps of A) providing a cellulose derivative having a moisture content of from 60 to 95 percent, based on the total weight of the moist cellulose derivative, B) grinding and partially drying the moist cellulose derivative in a gas-swept impact mill; and C) contacting the ground and partially dried cellulose derivative with an additional amount of a drying gas outside the gas-swept impact mill. The obtained particulate cellulose derivative has a high untapped bulk density and a good flowability.

Abstract: A process is described for the preparation of freeze-dried pharmaceutical compositions of mitomycin C, which are characterized by high stability and can be rapidly reconstituted to form solutions.

Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain a matrix with gelling polymer and disintegrant, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.

Abstract: An instantly floating gastroretentive drug formulation comprising at least one functionalized natural and/or synthetic calcium carbonate-comprising mineral and at least one pharmaceutically active ingredient and at least one formulating aid wherein said functionalized natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source.

Abstract: The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anaemia, chronic renal disorders and renal insufficiency.

Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid ?9-tetrahydrocannabinol (THC). More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment 30-90 wt % of a granulate; 10-70 wt % of lactose; and 0-30 wt % of other tablet excipients; wherein the granulate contains: a. 2-5 wt % of ?9-tetrahydrocannabinol; b. 2-20 wt % of sucrose fatty acid mono-ester; c. 50-96 wt % of lactose; d. 0.05-0.6 wt % of antioxidant; and e. 0-25 wt % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of spasticity and pain caused by multiple sclerosis, neurophatic pain, chronic pain, behavioral disturbance by Alzheimer's disease, stroke, spinal cord injury, peripheral neuropathy, neurogenic pain, nociceptive pain and nausea.

Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.

Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: Pharmaceutical compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof adapted so that release does not take place in the stomach is provided.

Abstract: The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.

Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.

Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.

Abstract: A method of making a hyperbranched amphiphilic polyester compound includes drying under vacuum a mixture of 2-(4-hydroxybutyl)-malonic acid and p-toluene sulphonic acid as catalyst. The vacuum is then released with a dry inert gas after drying. The dried mixture is heated under the inert gas at a temperature sufficient for polymerization. The inert gas is evacuated while continuing to heat the mixture. The formed polymer is then dissolved in dimethylformamide and precipitated out by adding methanol. Modifications of the method yield nanoparticles of polyesters having properties suited for coencapsulating fluorescent dyes together with therapeutic drugs, resulting in theranostic nanoparticles, that is, nanoparticles useful in both therapeutic treatments and diagnostic methods.

Abstract: In this work we have targeted two aspects of GQDs, Size and ROS to reduce their cytotoxicity. Small size can damage cell organelles and production of ROS (reactive oxygen species) can hamper cell machinery in multiple ways. We have shown that cytotoxicity can be significantly reduced by embedding GQDs inside the PEG matrix rather than creating a thin shell around each GQD. Thin PEG shell around GQD can control ROS production but cannot circumvent the toxicity due to small size. Thus it was essential to solve both the issues. We have used a simple electrochemical method (12 h at room temperature) for synthesizing GQDs and embedded them in PEG matrix via a simple one step hydrothermal reaction (24 h at 160° C.) involving only GQDs, PEG, and deionized water. The P-GQDs formed after hydrothermal reaction show nanoparticles of diameter of ˜80-100 nm containing GQDs entrapped in PEG matrix. MTT assay showed significant 60% cells viability at a very high concentration of 5.

Abstract: The invention generally relates to polymeric particles suitable for transporting bioactive agents across mucosal barriers. The invention also relates to methods of making and using those polymeric particles.

Abstract: A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition comprising a preformed excipient mixture comprising an acidic component and an alkaline thermoplastic matrix-forming material, e.g. polymer. The excipient mixture is formed before blending with an alkaline labile drug. The blend is then hot-melt extruded to form the HME composition. By so doing, the acidic component is able to neutralize or render moderately acidic the excipient mixture. This particular process has been shown to substantially reduce the degradation of an alkaline labile drug during hot-melt extrusion. The excipient mixture softens or melts during hot-melt extrusion. It can dissolve or not dissolve drug-containing particles during extrusion.

Abstract: Described are oligomeric/polymeric silicone fluids useful in transdermal drug delivery systems. Also described are compositions for the transdermal delivery of a drug comprising a drug-containing polymer matrix comprising a drug; a carrier polymer, and an oligomeric/polymeric silicone fluid having repeating —Si(CH3)2—O— units. Related methods and uses also are described.